Home » Stocks » Galecto

Galecto, Inc. (GLTO)

Galecto will go public soon. The estimated IPO date is October 29, 2020.
Stock Price: $14.00 - $16.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 368.78M
Revenue (ttm) n/a
Net Income (ttm) -47.88M
Shares Out 24.59M
EPS (ttm) -1.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 368.78M
Enterprise Value 332.94M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 24.59M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.95
FCF / Share -1.65
Dividend n/a
Dividend Yield n/a
Earnings Yield -12.98%
FCF Yield -10.97%
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio -9.11
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -41.85M
Net Income -47.88M
Free Cash Flow -40.46M
Net Cash 35.84M
Net Cash / Share 1.46
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-38.97-12.91
Net Income-36.51-15.87
Operating Cash Flow-36.51-15.87
Capital Expenditures-0.33-
Free Cash Flow-36.83-15.87
Cash & Equivalents11.2930.99
Net Cash / Debt11.2930.99
Book Value-71.15-33.84
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Galecto, Inc.
Country Denmark
Employees 20
CEO Hans T. Schambye

Stock Information

Ticker Symbol GLTO
Stock Exchange NASDAQ
Industry Biotechnology
Unique Identifier NASDAQ: GLTO
IPO Date October 29, 2020


Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life. Our lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. We are developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung that affects approximately 100,000 people in the United States. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence.